

Review Article

Effect of noninvasive respiratory support on interstitial lung disease with acute respiratory failure: A systematic review and meta-analysis

Natthawan Sanguanwong^{1,2}, Nattawat Jantarangsi³, Jinjuta Ngeyvijit⁴, Natthida Owattanapanich⁵, Vorakamol Phoophiboon^{6,7,8}^a

¹ Department of Physiology, Faculty of Medicine, Chulalongkorn University, ² Excellence Center for Sleep Disorders, King Chulalongkorn Memorial Hospital, ³ Department of Internal Medicine, Buddhachinaraj Hospital, ⁴ Pulmonary and Critical Care Medicine, Department of Medicine, Chaophraya Abhaibhubejhr Hospital, ⁵ Trauma Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, ⁶ Excellence Center for Critical Care Medicine, King Chulalongkorn Memorial Hospital, ⁷ Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, ⁸ Department of Critical Care Medicine, St. Michael's Hospital

Keywords: interstitial lung disease, noninvasive positive pressure ventilation, noninvasive ventilation, high-flow nasal cannula, acute respiratory failure, acute exacerbation, noninvasive respiratory support

<https://doi.org/10.29390/001c.89284>

Canadian Journal of Respiratory Therapy

Vol. 59, 2023

Abstract

Background

Primary studies have demonstrated the effectiveness of noninvasive respiratory supports, including noninvasive positive pressure ventilation (NIPPV) and high flow nasal cannula (HFNC), for improving oxygenation and ventilation in patients with interstitial lung diseases (ILDs) and acute respiratory failure (ARF). These studies have not been synthesized and are not included in current practice guidelines. This systematic review with meta-analysis synthesizes studies that compared the effectiveness of NIPPV, HFNC and conventional oxygen therapy (COT) for improving oxygenation and ventilation in ILD patients with ARF.

Methods

MEDLINE, EMBASE and the Cochrane Library searches were conducted from inception to August 2023. An additional search of relevant primary literature and review articles was also performed. A random effects model was used to estimate the PF ratio (ratio of arterial oxygen partial pressure to fractional inspired oxygen), PaCO₂ (partial pressure of carbon dioxide), mortality, intubation rate and hospital length of stay.

Results

Ten studies were included in the systematic review and meta-analysis. Noninvasive respiratory supports demonstrated a significant improvement in PF ratio compared to conventional oxygen therapy (COT); the mean difference was 55.92 (95% CI [18.85-92.99]; $p=0.003$). Compared to HFNC, there was a significant increase in PF ratio in NIPPV (mean difference 0.45; 95% CI [0.12-0.79]; $p=0.008$). There were no mortality and intubation rate benefits when comparing NIPPV and HFNC; the mean difference was 1.1; 95% CI [0.83-1.44]; $p=0.51$ and 1.86; 95% CI [0.42-8.33]; $p=0.42$, respectively. In addition, there was a significant decrease in hospital length of stay in HFNC compared to NIPPV (mean difference 9.27; 95% CI [1.45 – 17.1]; $p=0.02$).

^a *Corresponding author

Vorakamol Phoophiboon, MD, MSc, EDIC
Division of Critical Care Medicine, Department of Medicine,
Faculty of Medicine, Chulalongkorn University,
1873 King Chulalongkorn Memorial hospital,
Pathumwan, Bangkok 10800, Thailand
Rakamol@hotmail.com

Conclusions

Noninvasive respiratory supports might be an alternative modality in ILDs with ARF. NIPPV demonstrated a potential to improve the PF ratio compared to HFNC. There was no evidence to support the benefit of NIPPV or HFNC in terms of mortality and intubation rate.

INTRODUCTION

Interstitial lung diseases (ILDs) are groups of diffuse parenchymal lung conditions with overlapping clinical presentation and radiological features. The 2013 Global Burden of Disease Study reported that ILDs were ranked 40th in relation to global years of mortality.¹ The global incidence of ILDs ranged from 1 to 31.5 per 100,000 patients per year, and the prevalence ranged from 6.3 to 7.1 per 100,000.² The diagnosis and treatment of ILDs require a multidisciplinary approach. Professions involved in the management of ILDs include but are not limited to, respirologists, radiologists and pathologists.³ The trajectory of ILDs is unpredictable; thus, prognostication may be challenging. Interstitial lung disease classification and terminology have been modified and updated over the past decade.⁴ The American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association have collaborated to endorse practice guidelines for ILD management.³⁻⁶

Hypoxemia in ILDs consists of multiple physiologic derangements, including diffusion impairment, ventilation-perfusion mismatch, and abnormalities of the pulmonary vasculature leading to pulmonary hypertension.⁷ Chronic repetitive inflammatory processes and aberrant wound healing can lead to progressive destruction in alveolar units (i.e., fibrosis) and consequently limitations to oxygen diffusion from alveoli to capillaries.^{9,10} Consequently, oxygen supplementation is a main treatment approach in both acute and chronic respiratory failure patients. However, achieving targeted oxygen levels can be challenging. Acute exacerbations of ILDs have been reported to be the most common causes of respiratory deterioration and are associated with poor outcomes. Specifically, acute exacerbation of ILDs accounts for 29-55% of respiratory hospitalizations and 20-33% of lower respiratory tract infections.¹¹ ILD patients who require mechanical ventilation generally have poor outcomes due to the irreversible nature of their disease.¹³⁻¹⁷ Although extracorporeal membrane oxygenation (ECMO) is stated as a rescue modality in ILDs with refractory hypoxemia, it is unable to alter the mortality, particularly when patients do not qualify for lung transplantation.¹⁸

Current practice guidelines reflect certain favourable outcomes associated with noninvasive positive pressure ventilation (NIPPV) or high flow nasal cannula (HFNC) in selected acute respiratory failure (ARF) patients.¹⁹⁻²¹ Although ILDs were not included in those recommendations, primary studies suggest that NIPPV or HFNC might be potential approaches in this subgroup.²²⁻²⁴ The common ventilatory settings of NIPPV used in acute and/or chronic respiratory failure are known as Continuous Positive Airway Pressure (CPAP) and Bilevel Positive Airway Pressure (Bi-

PAP).²¹ This review synthesizes current studies that compared the effectiveness of noninvasive respiratory supports (NIPPV and/or HFNC) and conventional oxygen therapy (COT) for improving oxygenation and ventilation in ILD patients with ARF.

METHOD

ELIGIBILITY CRITERIA

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.²⁵ We applied the following inclusion criteria: experimental studies (randomized, quasi-randomized, prospective and retrospective trials) that examined the benefit of NIPPV or HFNC on patients with ILDs and ARF and/or distress; adults (aged ≥ 18 years). The exclusion criteria were case reports and case series. The outcome measures included improvements in oxygenation and ventilation at 24 h or as defined by the study, using $\text{PaO}_2/\text{FiO}_2$ (PF ratio) and PaCO_2 , respectively; mortality; intubation rate; hospital length of stay and complications.

INFORMATION SOURCES AND SEARCH STRATEGY

Systematic literature searches were conducted for studies published from inception to August 6, 2023, in MEDLINE, EMBASE and the Cochrane Library. Search terms included the medical subject headings (MeSH) “noninvasive positive pressure ventilation” OR “noninvasive ventilation” OR “high flow nasal cannula” AND “interstitial lung disease” (**Supplemental Table 1**). There were no language restrictions.

STUDY SELECTION AND DATA COLLECTION

Two authors (VP and NO) independently performed article selection by title and abstract screening based on predetermined eligibility criteria. The references of the included studies were manually reviewed for additional eligible studies. Disagreements relating to any aspect of the data extraction process were discussed and resolved by a third reviewer (JN), with the final decision made by consensus. The full-text articles of the selected studies were reviewed independently for the final study selection. The data were extracted and analyzed from the included studies (NS, VP, and NJ).

QUALITY ASSESSMENT

Two investigators (VP and NO) assessed the quality of included studies using the Cochrane risk-of-bias tool for randomized trials (RoB 2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) for

non-randomized studies tool^{25,26} (Table 1, Supplemental Tables 2 and 3).

STATISTICAL ANALYSIS

All statistical analyses were performed using Review Manager (RevMan) version 5.4.1 (The Cochrane Collaboration, 2020). We extracted the proportions and 95% confidence intervals (CIs) from each study and pooled them using the random effect model. Cochran's Q test was performed and quantified using the I^2 statistic to determine the statistical heterogeneity among the included studies. An I^2 value of 0% to 25% represents insignificant heterogeneity, greater than 25% but less than or equal to 50% represents low heterogeneity, greater than 50% but less than or equal to 75% represents moderate heterogeneity, and greater than 75% represents high heterogeneity. *P*-values less than 0.05 were considered statistically significant. A funnel plot visualized the presence of a publication bias (Supplemental Figure 1). The protocol for this study was registered at www.inplasy.com (No. 202260104). Ethical approval was not required.

RESULTS

SEARCH RESULTS

Systematic literature searches identified 1,000 unique citations. A review of titles and abstracts resulted in the elimination of 981 studies. The full text of these 19 studies was reviewed to determine eligibility (Figure 1). This systematic review included ten studies (including a total of 480 patients). One randomized control trial, one prospective cohort study and eight retrospective cohort studies were included.

Study characteristics are described in Table 1. The included studies consisted of NIPPV application (four studies),²⁷⁻³⁰ HFNC application (two studies)^{31,32} and NIPPV and HFNC application (four studies).³³⁻³⁶ Idiopathic pulmonary fibrosis (IPF) was a major type of ILDs in this study (239 patients, 49.7% of total ILDs). Three of ten studies included cardiac failure in the definition of acute exacerbation.^{28,34,36} The ICU was the main location of the interventions (seven of ten studies). The mean duration of noninvasive respiratory supports was 5.76 ± 8.55 days. The mean initial PF ratio before noninvasive respiratory supports was 156.94 ± 64.74 .

PUBLICATION BIAS ASSESSMENT

The funnel plot of the PF ratio outcome of the conventional oxygen therapy and noninvasive respiratory supports was symmetric and showed no publication bias (Supplemental Figure 1).

EFFECT OF INTERVENTION

PRIMARY OUTCOME

The PF ratio (a clinical indicator of hypoxemia) is the primary outcome measure of the effect of noninvasive respi-

ratory supports (NIPPV or HFNC) compared to COT on ILD patients with ARF. Of ten studies, pooled analysis was performed on six (NIPPV-four studies, HFNC-two studies)^{27-32, 37} using a random-effect model. This analysis showed that noninvasive respiratory support significantly improved the PF ratio compared to COT. The mean difference was 55.92 (95% CI [18.85–92.99]; $I^2=88\%$; $p=0.003$). In subgroup analysis, both NIPPV and HFNC demonstrated a significant improvement in oxygenation compared to COT (mean difference 51.06, 95% CI [11.88–90.24]; $I^2=79\%$; $p=0.01$ and (mean difference 67.27, 95% CI [1.17–133.37]; $I^2=38\%$; $p=0.05$), respectively (Figure 2).

SECONDARY OUTCOMES

Secondary outcomes measures included i.) PaCO_2 (a clinical indicator of alveolar ventilation) to examine the effect of noninvasive respiratory supports (NIPPV or HFNC) compared to COT on ILD patients with ARF, ii.) PF ratio to compare the effects of NIPPV with HFNC, iii.) mortality, iv.) intubation rate and v.) hospital length of stay. Four studies (three studies–NIPPV and one study–HFNC)^{27,28, 30,32} reported the effects of noninvasive respiratory supports on PaCO_2 outcomes. There was no significant difference in PaCO_2 reduction between COT and noninvasive respiratory supports. The mean difference was 3.82 (95% CI [-0.25–7.88]; $I^2=0\%$; $p=0.07$). (Figure 3).

Four studies compared NIPPV directly to HFNC in ILD patients with ARF. Three of four studies³³⁻³⁵ demonstrated a significant increase in PF ratio for NIPPV when compared to HFNC (mean difference 0.45; 95% CI [0.12–0.79]; $I^2=0\%$; $p=0.008$) (Figure 4). The comparison between NIPPV and HFNC revealed that neither method demonstrated a significant impact on mortality (four studies)³³⁻³⁶ (Figure 5) or intubation rates (two studies)^{35,36} (Figure 6). Risk Ratio (RR) was 1.1; 95% CI [0.83–1.44]; $I^2=67\%$; $p=0.51$ and 1.86; 95% CI [0.42–8.33]; $I^2=54\%$; $p=0.42$, respectively. Lastly, patient groups receiving HFNC experienced significantly shorter hospital lengths of stay when compared to those receiving NIPPV (two studies^{33,34}; the mean difference was 9.27 (95% CI [1.45–17.1]; $I^2=17\%$; $p=0.02$) (Figure 7).

OTHER EFFECTS OF NIPPV AND HFNC

Two studies conducted on do-not-intubate patients (DNI) examined the effect of oral alimentation and the time of loss of cognitive function before death as outcomes^{33,34}. The HFNC showed a significant oral intake ability before death compared to NIPPV in Imai et al. and Koyauchi et al.; $p=0.002$ and $p=0.037$, respectively. In addition, there was significantly less cognitive dysfunction in HFNC compared to NIPPV in Imai et al. and Koyauchi et al.; $p=0.03$ and $p=0.037$, respectively.

Koyauchi et al. reported eight adverse events, including seven in patients receiving NIPPV and one in a patient receiving HFNC.³⁴ Specifically, seven of 30 patients (23.3%) receiving NIPPV reported injuries (5 reports of skin damage, one gingival ulcer and one pneumo-mediastinum), while one of 54 patients (1.85%) receiving HFNC reported nasal bleeding. In addition, patients' requests for interface

Table 1. Characteristics of included studies.

Study and Country	Age (years; mean \pm SD) and Sex (%)	Study Design	Number of patients (N)	Patient Characteristics	Duration of NIPPV/HFNC (days)	Device setting (mmHg) /Initial PF ratio	Location of interventions	Overall risk of bias (ROBINS-I or RoB 2)
Yokoyama T et al. 2010, Japan	72.3 \pm 7.7 Male 63.6%	Retrospective cohort study	11 - NIPPV	IPF with ARF	5.4 \pm 3.8	CPAP - PEEP 10.1 \pm 2.5 BiPAP - IPAP 15 \pm 3.3, EPAP 10.2 \pm 2.9 /138.9 \pm 55.7	University hospital, N/A	Serious
Gungor G et al. 2013, Turkey	66 \pm 3.2 Male 59.2%	Retrospective cohort study	75 - NIPPV	ILDs with ARF 56 - IPF (no biopsy proven) 7 - CVD 8 - Silicosis 2 - Drug induced ILD 2 - EP	5 \pm 3.7	BiPAP - Target PS to keep TV 6-8 ml/Kg, PEEP 5-7 /143 \pm 60.7	Pulmonary disease and Thoracic surgery hospital, ICU	Moderate
Aliberti S et al. 2014, Italy	71 \pm 3 Male 63.3%	Retrospective cohort study	60 - NIPPV	ILDs with ARF 28 - IPF 8 - CTD 3 - COP 1 - HP 16 - idiopathic NSIP 4 - others	N/A	CPAP - PEEP 8 \pm 1.48 BiPAP - PS 15 \pm 7.4, PEEP 5 \pm 2.2 /125 \pm 57.8	General hospital, RICU	Moderate
Shebl E et al. 2018, Egypt	61.1 \pm 12.3 Male 35.7%	Prospective randomized control trial	36 - NIPPV 34 - HFNC	ILDs with ARF 19 - IPF 9 - HP 9 - CTD 2 - Drug induced ILD 4 - LCH 3 - Pneumoconiosis 7 - Sarcoidosis 17 - non-IPF IIP	N/A	NIPPV - CPAP with PEEP up to 12 HFNC - 60 L/min /172 \pm 48.5	General hospital, ICU	Some concerns
Koyauchi T et al. 2018, Japan	78.4 \pm 2.8 Male 72.6%	Retrospective cohort study	30 - NIPPV 54 - HFNC	ILDs with ARF in DNI patients 44 - IPF 27 - Non-IPF IIP 10 - CTD	6 \pm 8.9	NIPPV - N/A HFNC - 40 \pm 14.8 L/min /N/A	General hospital, N/A	Serious

				2 - HP 1 - Sarcoidosis				
Vianello A et al. 2019, Italy	68.6 ± 9.5 Male 82.4%	Retrospective cohort study	17 - HFNC	IPF with ARF	N/A	NIPPV - BiPAP target TV 6-8 ml/Kg, PEEP 5 HFNC - up to 70 L/min /145 ± 180	University Hospital, RICU	Moderate
Imai R et al. 2019, Japan	78.2 ± 4.1 Male 48.6%	Retrospective cohort study	14 - NIPPV 21 - HFNC	ILDs with ARF in DNI patients 13 - IPF 11 - CTD 11 - others	8 ± 17.8	NIPPV - BiPAP PS as tolerate, PEEP 5 HFNC - up to 60 L/min /N/A	General hospital, N/A	Moderate
Omote N et al. 2020, Japan	70.9 ± 3.9 Male 81.3%	Retrospective cohort study	19 - NIPPV 13 - HFNC	ILDs with ARF 20 - IPF 8 - CTD 4 - others	N/A	NIPPV - BiPAP PS 2 ± 2.9, PEEP 6 ± 2.9 HFNC - up to 50 L/min /138.5 ± 57	University hospital, ED and ICU	Serious
Koyauchi T et al. 2020, Japan	78 ± 2.3 Male 77.3%	Retrospective cohort study	66 - HFNC	ILDs with ARF 31 - IPF 35 - non-IPF	6.5 ± 7.4	HFNC - 40 ± 3.7 L/min /199.18 ± 53.9	University Hospital, ICU	Serious
Ahmed N et al. 2023, Egypt	45.67 ± 14.48 Male 30%	Prospective cohort study	30 - NIPPV	ILDs with ARF 16 - HP 14 - others (non-IPF)	2.93 ± 1.26	BiPAP - PS 4, PEEP 4 /160.67 ± 41.26	University Hospital, RICU	Moderate

Abbreviation: PF ratio – the ratio of arterial oxygen partial pressure to fractional inspired oxygen, NIPPV – noninvasive positive pressure ventilation, HFNC – high flow nasal cannula, IPF – idiopathic pulmonary fibrosis, ARF – acute respiratory failure, CPAP – continuous positive airway pressure, BiPAP – bi-level positive airway pressure, PEEP – positive end-expiratory pressure, PS – pressure support, IPAP – inspiratory positive airway pressure, EPAP – expiratory positive airway pressure, ILDs – interstitial lung diseases, CVD – collagen vascular disease, EP – eosinophilic pneumonia, CTD – connective tissue disease, COP – cryptogenic organizing pneumonia, HP – hypersensitivity pneumonitis, NSIP – non-specific interstitial pneumonia, LCH – Langerhans cell histiocytosis, IIP – idiopathic interstitial pneumonia, DNI – do not intubation, ED – emergency department, ICU – intensive care unit, RICU – respiratory intensive care unit.




Figure 1. Flow diagram of the article selection procedure based on the PRISMA guideline.




Figure 2. Effect of noninvasive respiratory supports on PF ratio.

discontinuation were significantly higher for NIPPV (3 of 30; 10%) compared to HFNC (0 of 54), $p=0.043$.

In Yogoyama et al.,³⁷ the time to initiate NIPPV determined survival outcomes significantly ($p=0.006$). The survivor group showed 2.3 ± 2.9 days to initiate NIPPV, whereas the non-survivor group showed 4.4 ± 3.1 days.

Gungor et al.²⁸ demonstrated the APACHE II score greater than 20 and continuous NIPPV demand indicated a significant risk for NIPPV failure: hazard ratio (HR) 2.77

(95% CI 1.19–6.45); $p<0.02$, and HR 5.12 (95% CI 1.44–18.19); $p<0.01$, respectively. On the contrary, the result from Vianello et al.³² conducted in HFNC demonstrated a significantly higher APACHE II score in a success group than a failure group ($p=0.043$).



Figure 3. Effect of noninvasive respiratory supports on PaCO_2 .

Figure 4. Effect of NIPPV or HFNC on PF ratio.




Figure 5. Effect of NIPPV or HFNC on mortality.




Figure 6. Effect of NIPPV or HFNC on intubation rate.




Figure 7. Effect of NIPPV or HFNC on hospital length of stay.

DISCUSSION

To our knowledge, this is the first systematic review with meta-analysis to compare the effectiveness of noninvasive respiratory supports (NIPPV and/or HFNC) and conventional oxygen therapy (COT) for improving oxygenation and ventilation in ILD patients with ARF.

Compared with COT, noninvasive respiratory supports significantly increased PF ratio. The subgroup analysis suggested a significant benefit of both NIPPV and HFNC on PF ratio. When comparing NIPPV and HFNC, PF ratio was significantly increased in NIPPV. There was no difference in mortality and intubation rate between the two groups. However, the hospital length of stay showed a significantly shorter duration with HFNC compared to NIPPV. The number of reported serious complications (i.e., pneumothorax, nasal bleeding) was low.

According to ERS recommendation, NIPPV is recommended for ARF with chronic obstructive pulmonary disease exacerbation and/or weaning, cardiogenic pulmonary edema and immunocompromised patients.²¹ In contrast, HFNC is strongly recommended in acute hypoxemic respiratory failure and conditionally recommended in any high-risk features following extubation or in high-risk and/or obese patients following cardiac or thoracic surgery.²⁰ Notwithstanding, none of the studies explicitly evaluated patients with ILDs.

In our study, noninvasive respiratory supports significantly improved PF ratio compared to COT, and both NIPPV and HFNC subgroups demonstrated this improvement. An earlier systematic review determined that NIPPV improves ventilation-perfusion mismatch and decreases the work of respiratory muscles³⁸ Furthermore, NIPPV has been described as decreasing venous return against pulmonary edema, improving oxygenation, particularly in concomitant cardiac dysfunction patients.³⁹ Similarly, HFNC subgroup analysis demonstrated a significant improvement on PF ratio compared to COT. Prior studies have demonstrated that HFNC improves mucociliary clearance, reducing upper-airway dead space, generating a low level of positive airway pressure with consistent FiO_2 regardless of inspiratory flow rate and ultimately providing comfort for the patient.^{40,41} In our study, PF ratio was significantly increased in NIPPV. This result may be potentially explained by lung recruitment after receiving adequate positive pressure.^{42,43}

Noninvasive respiratory supports did not show a significant reduction in carbon dioxide (CO_2) levels. This may reflect many variables (patient's conditions, various settings

of HFNC and NIPPV (CPAP and/or BiPAP), different types of interfaces) across studies. Notably, the risk of carbon dioxide rebreathing was higher on helmet interface.^{44,45} In a recent meta-analysis of trials of acute hypoxemic respiratory failure, treatment with noninvasive respiratory support strategies was associated with a lower risk of death and intubation⁴⁶; however, our study demonstrated none of those benefits. Of note, acute pneumonia was a frequent cause of acute hypoxemic respiratory failure in the aforementioned meta-analysis, and the high reversible potential of this acute pneumonia may have contributed to the favourable outcomes described. In our study, HFNC showed a significant decrease in hospital length of stay compared to NIPPV. This finding was consistent with recent studies demonstrating decreased length of stay in patients with hypercapnic respiratory failure and hypoxemia related to COVID pneumonia when using HFNC.^{47,48} Recent studies have proposed that diaphragm atrophy, a result of positive pressure ventilation, may cause prolonged hospital length of stay in NIPPV patients; however, these positive pressure effects were only related to mechanical ventilation.^{49,50} Therefore, this issue may require further scientific study.

A strength of this meta-analysis is that it includes a large number of subjects with ILDs with ARF. Our meta-analysis was guided by a registered protocol and strengthened by an extensive search, duplicate citation screening, data abstraction and conducting of prespecified subgroup analyses. However, there are limitations. First, data was obtained primarily from retrospective studies (eight of ten). Thus, the overall level of evidence is low to moderate. Second, summary estimates were limited by heterogeneous types of ILDs, which may interfere with a treatment response and an overall prognosis.

CONCLUSION

In summary, NIPPV or HFNC might be an alternative modality in ILD patients with ARF, mainly to avoid the negative consequences of intubation. NIPPV showed a significant improvement in PF ratio compared to HFNC. However, there were no mortality and intubation rate benefits when comparing NIPPV and HFNC.

CONTRIBUTORS

NS, VP, and NO conducted the literature searches and resolved discrepancies between citation reviewers, selected studies meeting inclusion criteria, assessed study quality, conducted risk of bias assessment, double-checked data entry, and prepared initial and subsequent drafts of the manuscript and revised versions. NS, NJ and JN conducted literature searches, assisted with screening articles' study quality, provided methodologic guidance, and integrated comments into the manuscript. All authors revised and approved the final version of the manuscript.

FUNDING

This study did not receive any funding in any form.

PRIOR CONFERENCE PRESENTATION

This study was presented as a poster presentation at the 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM), March 21, 2023.

COMPETING INTERESTS

The authors declare no conflict of interest.

ETHICS APPROVAL

Not required.

DATA AVAILABILITY STATEMENT

Data are available on request.

Submitted: January 20, 2023 EDT, Accepted: October 13, 2023 EDT



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-NC-4.0). View this license's legal deed at <https://creativecommons.org/licenses/by-nc/4.0> and legal code at <https://creativecommons.org/licenses/by-nc/4.0/legalcode> for more information.

REFERENCES

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117–171. doi:10.1016/S0140-6736(14)61682-2
2. Kaul B, Cottin V, Collard HR, Valenzuela C. Variability in Global Prevalence of Interstitial Lung Disease. *Front Med*. 2021;8:751181. doi:10.3389/fmed.2021.751181
3. Guler SA, Corte TJ. Interstitial Lung Disease in 2020: A History of Progress. *Clin Chest Med*. 2021;42(2):229–239. doi:10.1016/j.ccm.2021.03.001
4. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med*. 2013;188(6):733–748. doi:10.1164/rccm.201308-1483st
5. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2018;198(5):e44–e68. doi:10.1164/rccm.201807-1255st
6. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline [published correction appears in *Am J Respir Crit Care Med*. 2021 Jan 1;203(1):150–151] [published correction appears in *Am J Respir Crit Care Med*. 2022 Aug 15;206(4):518]. *Am J Respir Crit Care Med*. 2020;202(3):e36–e69. doi:10.1164/rccm.202005-2032st
7. Agustí AGN, Roca J, Gea J, Wagner PD, Xaubet A, Rodríguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. *Am Rev Respir Dis*. 1991;143(2):219–225. doi:10.1164/ajrccm/143.2.219
8. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. *Curr Opin Pulm Med*. 2005;11(5):452–455. doi:10.1097/01.mcp.0000174250.38188.6d
9. Glasser SW, Hardie WD, Hagood JS. Pathogenesis of Interstitial Lung Disease in Children and Adults. *Pediatr Allergy Immunol Pulmonol*. 2010;23(1):9–14. doi:10.1089/ped.2010.0004
10. Plantier L, Cazes A, Dinh-Xuan AT, Bancal C, Marchand-Adam S, Crestani B. Physiology of the lung in idiopathic pulmonary fibrosis. *Eur Respir Rev*. 2018;27(147):170062. doi:10.1183/16000617.0062-2017
11. Teramachi R, Kondoh Y, Kataoka K, et al. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis. *Respir Med*. 2018;143:147–152. doi:10.1016/j.rmed.2018.09.011
12. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. *Eur Respir J*. 2011;37(2):356–363. doi:10.1183/09031936.00159709
13. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. *Chest*. 2001;120(1):209–212. doi:10.1378/chest.120.1.209
14. Rangappa P, Moran JL. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. *Crit Care Resusc*. 2009;11(2):102–109. doi:10.1016/S1441-2772(23)01533-8
15. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. *Can Respir J*. 2004;11(2):117–122. doi:10.1155/2004/379723
16. Fernández-Pérez ER, Yilmaz M, Jenad H, et al. Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease. *Chest*. 2008;133(5):1113–1119. doi:10.1378/chest.07-1481
17. Faverio P, De Giacomi F, Sardella L, et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. *BMC Pulm Med*. 2018;18(1):70. doi:10.1186/s12890-018-0643-3
18. Trudzinski FC, Lepper PM. Extrakorporale Membranoxygenierung bei akutem respiratorischem Versagen: Outcome von Patienten mit interstitieller Lungenerkrankung [Extracorporeal membrane oxygenation for treatment of acute respiratory failure: Outcome of patients with interstitial lung disease]. *Med Klin Intensivmed Notfmed*. 2017;112(6):552–556. doi:10.1007/s00063-017-0326-5

19. Kang BJ, Koh Y, Lim CM, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. *Intensive Care Med.* 2015;41(4):623-632. [doi:10.1007/s00134-015-3693-5](https://doi.org/10.1007/s00134-015-3693-5)
20. Rochwerg B, Einav S, Chaudhuri D, et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. *Intensive Care Med.* 2020;46(12):2226-2237. [doi:10.1007/s00134-020-06312-y](https://doi.org/10.1007/s00134-020-06312-y)
21. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J.* 2017;50(2):1602426. [doi:10.1183/13993003.02426-2016](https://doi.org/10.1183/13993003.02426-2016)
22. Mollica C, Paone G, Conti V, et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. *Respiration.* 2010;79(3):209-215. [doi:10.1159/000225932](https://doi.org/10.1159/000225932)
23. Taniguchi H, Kondoh Y. Acute and subacute idiopathic interstitial pneumonias. *Respirology.* 2016;21(5):810-820. [doi:10.1111/resp.12786](https://doi.org/10.1111/resp.12786)
24. Arizono S, Oomagari M, Yanagita Y, Machiguchi H, Tawara Y, Yokomura K. Benefits of high-flow nasal cannula oxygen therapy on exercise capacity following acute exacerbation in ILD patients. *European Respiratory Journal.* 2020;56(suppl 64):4662. [doi:10.1183/13993003.congress-2020.4662](https://doi.org/10.1183/13993003.congress-2020.4662)
25. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6(7):e1000097. [doi:10.1371/journal.pmed.1000097](https://doi.org/10.1371/journal.pmed.1000097)
26. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ.* 2016;355:i4919. [doi:10.1136/bmj.i4919](https://doi.org/10.1136/bmj.i4919)
27. Aliberti S, Messinesi G, Gamberini S, et al. Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases. *BMC Pulm Med.* 2014;14:194. [doi:10.1186/1471-2466-14-194](https://doi.org/10.1186/1471-2466-14-194)
28. Güngör G, Tatar D, Saltürk C, et al. Why do patients with interstitial lung diseases fail in the ICU? a 2-center cohort study. *Respir Care.* 2013;58(3):525-531. [doi:10.4187/respcare.01734](https://doi.org/10.4187/respcare.01734)
29. Yokoyama T, Kondoh Y, Taniguchi H, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. *Intern Med.* 2010;49(15):1509-1514. [doi:10.2169/internalmedicine.49.3222](https://doi.org/10.2169/internalmedicine.49.3222)
30. Abo Elwafa GS, Ahmed NB, Abou Zeid AA, Abo Elhasab MA. Noninvasive ventilation in acute exacerbation of interstitial lung diseases. *Egypt J Chest Dis Tuberc.* 2023;72(1):99. [doi:10.4103/ecdt.ecdt_40_22](https://doi.org/10.4103/ecdt.ecdt_40_22)
31. Koyauchi T, Yasui H, Enomoto N, et al. Pulse oximetric saturation to fraction of inspired oxygen (SpO₂/FIO₂) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease. *Ther Adv Respir Dis.* 2020;14:1753466620906327. [doi:10.1177/1753466620906327](https://doi.org/10.1177/1753466620906327)
32. Vianello A, Arcaro G, Molena B, et al. High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis. *Ther Adv Respir Dis.* 2019;13:1753466619847130. [doi:10.1177/1753466619847130](https://doi.org/10.1177/1753466619847130)
33. Imai R, Tsugitomi R, Nakaoka H, Jinta T, Tamura T. Noninvasive Oxygenation Strategies for Acute Exacerbation of Interstitial Lung Disease: A Retrospective Single-center Study and a Review of the Literature. *Clin Pulm Med.* 2019;26(3):87-91. [doi:10.1097/cpm.0000000000000312](https://doi.org/10.1097/cpm.0000000000000312)
34. Koyauchi T, Hasegawa H, Kanata K, et al. Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders: A Retrospective Single-Center Study. *Respiration.* 2018;96(4):323-329. [doi:10.1159/000489890](https://doi.org/10.1159/000489890)
35. Omote N, Matsuda N, Hashimoto N, et al. High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: a retrospective observational study. *Nagoya J Med Sci.* 2020;82(2):301-313. [doi:10.18999/nagjms.82.2.301](https://doi.org/10.18999/nagjms.82.2.301)
36. Shebl E, Embarak S. High-flow nasal oxygen therapy versus noninvasive ventilation in chronic interstitial lung disease patients with acute respiratory failure. *Egypt J Chest Dis Tuberc.* 2018;67(3):270-275. [doi:10.4103/ejcdt.ejcdt_33_18](https://doi.org/10.4103/ejcdt.ejcdt_33_18)
37. Yokoyama T, Tsushima K, Yamamoto H, Koizumi T, Kubo K. Potential benefits of early continuous positive pressure ventilation in patients with rapidly progressive interstitial pneumonia. *Respirology.* 2012;17(2):315-321. [doi:10.1111/j.1440-1843.2011.02051.x](https://doi.org/10.1111/j.1440-1843.2011.02051.x)
38. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. *BMJ.* 2003;326(7382):185. [doi:10.1136/bmj.326.7382.185](https://doi.org/10.1136/bmj.326.7382.185)

39. Masip J, Peacock WF, Price S, et al. Indications and practical approach to non-invasive ventilation in acute heart failure. *Eur Heart J*. 2018;39(1):17-25. [doi:10.1093/eurheartj/ehx580](https://doi.org/10.1093/eurheartj/ehx580)
40. Ischaki E, Pantazopoulos I, Zakyntinos S. Nasal high flow therapy: a novel treatment rather than a more expensive oxygen device. *Eur Respir Rev*. 2017;26(145):170028. [doi:10.1183/16000617.0028-2017](https://doi.org/10.1183/16000617.0028-2017)
41. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated Humidified High-Flow Nasal Oxygen in Adults: Mechanisms of Action and Clinical Implications. *Chest*. 2015;148(1):253-261. [doi:10.1378/chest.14-2871](https://doi.org/10.1378/chest.14-2871)
42. Cosentini R, Brambilla AM, Aliberti S, et al. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. *Chest*. 2010;138(1):114-120. [doi:10.1378/chest.09-2290](https://doi.org/10.1378/chest.09-2290)
43. L'Her E, Deye N, Lellouche F, et al. Physiologic effects of noninvasive ventilation during acute lung injury. *Am J Respir Crit Care Med*. 2005;172(9):1112-1118. [doi:10.1164/rccm.200402-226oc](https://doi.org/10.1164/rccm.200402-226oc)
44. Chiumello D, Pelosi P, Carlesso E, et al. Noninvasive positive pressure ventilation delivered by helmet vs. standard face mask. *Intensive Care Med*. 2003;29(10):1671-1679. [doi:10.1007/s00134-003-1825-9](https://doi.org/10.1007/s00134-003-1825-9)
45. Navalesi P, Costa R, Ceriana P, et al. Non-invasive ventilation in chronic obstructive pulmonary disease patients: helmet versus facial mask. *Intensive Care Med*. 2007;33(1):74-81. [doi:10.1007/s00134-006-0391-3](https://doi.org/10.1007/s00134-006-0391-3)
46. Ferreyro BL, Angriman F, Munshi L, et al. Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-analysis. *JAMA*. 2020;324(1):57-67. [doi:10.1001/jama.2020.9524](https://doi.org/10.1001/jama.2020.9524)
47. He Y, Liu N, Zhuang X, Wang X, Ma W. High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis. *Ther Adv Respir Dis*. 2022;16:17534666221087847. [doi:10.1177/17534666221087847](https://doi.org/10.1177/17534666221087847)
48. Ovtcharenko N, Ho E, Alhazzani W, et al. High-flow nasal cannula versus non-invasive ventilation for acute hypercapnic respiratory failure in adults: a systematic review and meta-analysis of randomized trials. *Crit Care*. 2022;26(1):348. [doi:10.1186/s13054-022-04218-3](https://doi.org/10.1186/s13054-022-04218-3)
49. Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. *N Engl J Med*. 2008;358(13):1327-1335. [doi:10.1056/nejmoa070447](https://doi.org/10.1056/nejmoa070447)
50. Lindqvist J, van den Berg M, van der Pijl R, et al. Positive End-Expiratory Pressure Ventilation Induces Longitudinal Atrophy in Diaphragm Fibers. *Am J Respir Crit Care Med*. 2018;198(4):472-485. [doi:10.1164/rccm.201709-1917oc](https://doi.org/10.1164/rccm.201709-1917oc)

SUPPLEMENTARY MATERIALS

Supplementary Information

Download: <https://cjrt.ca/article/89284-effect-of-noninvasive-respiratory-support-on-interstitial-lung-disease-with-acute-respiratory-failure-a-systematic-review-and-meta-analysis/attachment/184767.docx>
